Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.
Menu
Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.
This program is made possible thanks to an independent educational grant from Ipsen.
Email: IME@springer.com
Your feedback helps us create the most relevant independent programs for your learning needs in the future.